Document is current
Any future updates will be listed below
-
Authors
Kurosky, Samantha K.
Cha-Silva, Ashley S.
Austin, Jenny
Mostaghimi, Arash
Kindred, Chesahna
Gauthier, Genevieve
Sadrarhami, Mojgan
Anderson, Peter
Ungar, Benjamin
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 17 April 2026
First Online: 30 May 2026
Declarations
:
: Samantha K Kurosky, Ashley S Cha-Silva, Genevieve Gauthier, and Mojgan Sadrarhami are employees of Pfizer Inc and may own stock/stock options in Pfizer Inc. Jenny Austin and Peter Anderson are employees of Adelphi Real World, Bollington, UK. Arash Mostaghimi reports personal fees from hims and hers, AbbVie, Sun Pharmaceuticals, Pfizer Inc, Digital Diagnostics, Lilly, ASLAN, Ingelheim, Figure 1 Co, and ACOM. Chesahna Kindred has been a speaker and/or advisory board member for Aerolase, Eli Lilly and Company, Janssen, Pfizer Inc, Regeneron, Sanofi, Selphyl, Sun Pharma, and UCB Pharma; has been a consultant for AbbVie, Novartis, and Pfizer Inc; has been a steering committee member for Janssen; and has been a journal editor for Cutis . Benjamin Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, Sun Pharma, UCB, Veradermics, and VRG Therapeutics.
: A complete description of the methods of the survey has been previously published and validated [ – ]. Permission was obtained from the owner of the Adelphi Real World AA II US DSP to use the database for this study. Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines, and as such it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Health Information Technology for Economic and Clinical Health Act legislation [ ].
